Tarsus Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
Is Raised Revenue Outlook Altering The Investment Case For Tarsus Pharmaceuticals (TARS)?
Is Tarsus Pharmaceuticals (TARS) Below Fair Value On Cash Flow?
Tarsus Pharmaceuticals (TARS) Could Be 31% Undervalued Following Record Q3 Sales
Tarsus to Participate in Upcoming Investor Conferences
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $97
Tarsus Pharmaceuticals Inc (TARS) (Q3 2026) Earnings Call Highlights: Record Xtendi Sales and ...
Tarsus (TARS) Q3 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $106
Tarsus Pharmaceuticals Q3 Earnings Call Highlights
Tarsus Pharmaceuticals (NASDAQ:TARS) Posts XDEMVY Beat but Acquisition Costs Weigh on Results
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
Tarsus Reports Third Quarter 2026 Financial Results
UPDATE: Tarsus Pharmaceuticals Q3 Adj. EPS $(0.78) Beats $(2.73) Estimate, Sales $194.569M Beat $186.598M Estimate
Tarsus Pharmaceuticals Q3 2026 Earnings Call Transcript
How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.